ESTRO 2024 - Abstract Book

S1722

Clinical - Lung

ESTRO 2024

20. Tanadini-Lang S, Rieber J, Filippi AR, et al. Nomogram based overall survival prediction in stereotactic body radiotherapy for oligo-metastatic lung disease. Radiother Oncol. 2017;123(2):182-188. doi:10.1016/j.radonc.2017.01.003

21. Shashank A, Shehata M, Morris DL, Thompson JF. Radiofrequency ablation in metastatic melanoma. J Surg Oncol. 2014;109(4):366-369. doi:10.1002/jso.23548

22. Clinical Commissioning Policy Stereotactic ablative radiotherapy (SABR) for patients with metachronous extracranial oligometastatic cancer (all ages) (URN: 1908) [200205P] NHS England. March 2020.

23. Owen D, Olivier KR, Mayo CS, et al. Outcomes of Stereotactic Body Radiotherapy (SBRT) treatment of multiple synchronous and recurrent lung nodules. Radiat Oncol. 2015;10(1). doi:10.1186/s13014-015-0340-9

24. Milano MT, Philip A, Okunieff P. Analysis of Patients With Oligometastases Undergoing Two or More Curative Intent Stereotactic Radiotherapy Courses. Int J Radiat Oncol Biol Phys. 2009;73(3):832-837. doi:10.1016/j.ijrobp.2008.04.073

25. Soga N, Yamakado K, Gohara H, et al. Percutaneous radiofrequency ablation for unresectable pulmonary metastases from renal cell carcinoma. BJU Int. 2009;104(6):790-794. doi:10.1111/j.1464-410X.2009.08459.x

26. Cao C, Wang D, Tian Dh et al. A systematic review and meta analysis of stereotactic body radiation therapy for colorectal pulmonary metastases. J Thorac Dis . 2019 Dec;11(12):5187-5198. doi: 10.21037/jtd.2019.12.12.

27. Klement RJ. Radiobiological parameters of liver and lung metastases derived from tumor control data of 3719 metastases. Radiother Oncol. 2017 May;123(2):218-226. doi: 10.1016/j.radonc.2017.03.014.

2174

Poster Discussion

Single versus multi-fraction SABR for early-stage primary lung and pulmonary oligometastases.

Ishaan Pillay 1 , Harriet Gee 2 , Eric Hau 2 , Anselm Ong 2 , Val Gebski 3,2

1 St. George Hospital, Cancer Care Centre, Sydney, Australia. 2 Westmead Hospital, Crown Princess Mary Cancer Care Centre, Sydney, Australia. 3 NHRMC clinical trials centre, University of Sydney, Sydney, Australia

Purpose/Objective:

Stereotactic ablative body radiotherapy (SABR/SBRT) is the standard of care for medically inoperable stage I-IIA non small cell lung cancer (NSCLC) and is increasingly guideline recommended for oligometastatic cancer to the lung. The randomized studies 1,2 comparing single-fraction (SF) to multi-fraction (MF) treatment for both primary lung cancer and pulmonary oligometastases, amenable to SABR, were powered for toxicity rather than local control. The primary objective of this study was to assess the 2-year rates of local failure (LF) for early-stage lung cancer and pulmonary oligometastases comparing the efficacy of SF SABR to MF SABR. The secondary focus was determining